Al­ny­lam's patisir­an grabs EMA ac­cel­er­at­ed re­view; CRISPR Ther­a­peu­tics, Case­bia en­ter mR­NA deal with Cure­Vac

→ Promis­ing Phase III da­ta on patisir­an have proven quite pro­duc­tive for Al­ny­lam, which an­nounced to­day that the EMA has grant­ed an ac­cel­er­at­ed as­sess­ment for the hered­i­tary AT­TR amy­loi­do­sis treat­ment. The RNAi ther­a­peu­tics com­pa­ny $AL­NY plans to ap­ply for mar­ket au­tho­riza­tion in Eu­rope at year-end 2017, rough­ly the same time frame as its in­tend­ed NDA fil­ing in the Unit­ed States, where the IV drug al­so got a fast track des­ig­na­tion. This news comes as Al­ny­lam pro­posed an­oth­er pub­lic of­fer­ing of shares, aim­ing to raise around $675 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER